JBIO — Jade Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1798749 ·
Last close
$14.42
Market Cap
$917.07M
52W High
$28.00
52W Low
$7.77
ADV30
915,353
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -58,916,000 | -55,765,000 | 472,113,000 | 107,250,000 | 32,198,000 |
| Mar 2026 | 0 | — | -43,445,000 | -40,368,000 | 319,433,000 | 55,085,000 | 22,971,000 |
| Dec 2025 | 0 | — | -34,979,000 | -31,932,000 | 349,781,000 | 88,438,000 | 17,263,000 |
| Sep 2025 | 0 | — | -27,401,000 | -25,175,000 | 202,450,000 | 50,106,000 | 23,104,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-100,013,000
Investing CF
$-255,476,000
Financing CF
$360,673,000
CapEx
$-60,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.09
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-214,757,000
Inventory
—
Receivables
—
ST Investments
$256,210,000
EBIT TTM
$-133,603,000
Pretax Income TTM
$-129,535,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -113,542,000 | -127,410,000 | 349,781,000 | 17,263,000 | 332,518,000 | -94,689,000 |
| Dec 2024 | — | — | — | 72,799,000 | 119,598,000 | -46,799,000 | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-27,430,000
OpCashFlow TTM
$0
Assets (Latest)
$127,418,000
Forward EPS
$-2.66
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $14.48 · call volume: 195 · put volume: 3Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALMS | ALUMIS INC. | $918.99M | $7.10 | — |
| HELP | CYBIN INC. | $921.29M | $12.61 | — |
| ANL | Adlai Nortye Group Ltd. | $912.15M | $15.53 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $900.00M | $48.18 | — |
| TBPH | Theravance Biopharma, Inc. | $884.18M | $17.03 | — |
News headlines (Yahoo Finance, 1h cache)
Jade Biosciences to Participate in Upcoming Conferences
2026-09-01 11:00 · Yahoo
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
2026-06-30 13:21 · Yahoo
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
2026-06-26 11:00 · Yahoo
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-06-05 20:01 · Yahoo
Jade Biosciences Announces Pricing of Public Offering of Common Stock
2026-06-04 02:58 · Yahoo
Jade Biosciences Announces Proposed Underwritten Public Offering
2026-06-03 20:01 · Yahoo
Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
2026-06-02 01:07 · Yahoo
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
2026-06-01 11:00 · Yahoo
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Mo
2026-05-29 20:05 · Yahoo
Assessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term Gains
2026-05-29 01:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.